| Abstract | An imbalance between prostacyclin (PGI2) and thromboxane A2 is observed in patients with scleroderma. Iloprost is a stable analogue of PGI2 with a plasma half-life of 20-30 min. Intravenous iloprost is effective in the treatment of Raynaud's phenomenon related to scleroderma, decreasing the frequency and severity of attacks. It also appears useful for the treatment of digital ulcers. Inhaled iloprost is an effective treatment for NYHA class III pulmonary arterial hypertension, either idiopathic primary or associated with a particular condition, such as scleroderma. Intravenous iloprost improves kidney vasospasm in patients with scleroderma. The possible benefits of sequential intravenous iloprost on the natural course of scleroderma require further investigation. |
| Authors | Eric Hachulla, David Launay, Pierre-Yves Hatron
(Affiliation: Centre de référence des maladies auto-immunes et maladies systémiques rares sclérodermie systémique, Service de médecine interne, Hôpital Claude Huriez, CHU, Université de Lille 2, F-59037 Lille Cedex, France. ehachulla at chru-lille.fr)
|
| Journal | Presse médicale (Paris, France : 1983)
(Presse Med)
Vol. 37
Issue 5 Pt 2
Pg. 831-9
(May 2008)
ISSN: 0755-4982 France |
| Vernacular Title | L'iloprost dans le traitement de la sclérodermie systémique. |
| PMID | 18035518
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
- Vasodilator Agents
- Iloprost
|
| Topics |
- Humans
- Hypertension
(drug therapy, etiology)
- Iloprost
(therapeutic use)
- Raynaud Disease
(drug therapy, etiology)
- Renal Circulation
(drug effects)
- Scleroderma, Systemic
(complications, drug therapy)
- Vasodilator Agents
(therapeutic use)
|
